BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3961730)

  • 1. Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets.
    Wade PJ; Lunt DO; Lad N; Tuffin DP; McCullagh KG
    Thromb Res; 1986 Jan; 41(2):251-62. PubMed ID: 3961730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific binding of [3H]-1-O-octadecyl Paf-acether to washed human platelets.
    Tuffin DP; Davey P; Dyer RL; Lunt DO; Wade PJ
    Adv Exp Med Biol; 1985; 192():83-96. PubMed ID: 3834789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers.
    Valone FH
    Thromb Res; 1987 Mar; 45(5):427-35. PubMed ID: 3590086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets.
    Kloprogge E; Akkerman JW
    Biochem J; 1984 Nov; 223(3):901-9. PubMed ID: 6150705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of the binding of platelet-activating factor to platelets of different animal species.
    Iñarrea P; Gomez-Cambronero J; Nieto M; Crespo MS
    Eur J Pharmacol; 1984 Oct; 105(3-4):309-15. PubMed ID: 6510472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites.
    Kiyomoto A; Sasaki Y; Odawara A; Morita T
    Circ Res; 1983 Feb; 52(2 Pt 2):I115-9. PubMed ID: 6831645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desaggregation of PAF-acether-aggregated platelets by verapamil and TMB-8 with reversal of phosphorylation of 40K and 20K proteins.
    Khan SN; Lane PA; Smith AD
    Eur J Pharmacol; 1985 Jan; 107(2):189-98. PubMed ID: 3920056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Ca2+ in regulating the catabolism of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in rabbit platelets.
    Touqui L; Shaw AM; Dumarey C; Jacquemin C; Vargaftig BB
    Biochem J; 1987 Jan; 241(2):555-60. PubMed ID: 3109377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition by calcium channel blockers of the binding of platelet-activating factor to human neutrophil granulocytes.
    Filep JG; Földes-Filep E
    Eur J Pharmacol; 1990 Nov; 190(1-2):67-73. PubMed ID: 1963851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-activating factor-induced calcium mobilization in human platelets and neutrophils: effects of PAF-acether antagonists.
    Selak MA; Smith JB
    J Lipid Mediat; 1989; 1(2):125-37. PubMed ID: 2519888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion of 3H-PAF acether by rabbit platelets is independent from aggregation: evidences for a novel metabolite.
    Touqui L; Jacquemin C; Vargaftig BB
    Biochem Biophys Res Commun; 1983 Feb; 110(3):890-3. PubMed ID: 6838557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycle.
    Touqui L; Jacquemin C; Dumarey C; Vargaftig BB
    Biochim Biophys Acta; 1985 Jan; 833(1):111-8. PubMed ID: 3967037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BN 52021 displaces [3H]paf-acether from, and inhibits its binding to intact human platelets.
    Korth R; Benveniste J
    Eur J Pharmacol; 1987 Oct; 142(3):331-41. PubMed ID: 3428349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba.
    Lamant V; Mauco G; Braquet P; Chap H; Douste-Blazy L
    Biochem Pharmacol; 1987 Sep; 36(17):2749-52. PubMed ID: 2820421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of platelet-activating factor 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced fibrinogen binding to human platelets.
    Kloprogge E; Mommersteeg M; Akkerman JW
    J Biol Chem; 1986 Aug; 261(24):11071-6. PubMed ID: 3015954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets.
    Simon MF; Chap H; Braquet P; Douste-Blazy L
    Thromb Res; 1987 Feb; 45(4):299-309. PubMed ID: 3576518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds.
    Baroggi N; Etienne A; Braquet P
    Agents Actions Suppl; 1986; 20():87-97. PubMed ID: 3028108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.
    Nunez D; Chignard M; Korth R; Le Couedic JP; Norel X; Spinnewyn B; Braquet P; Benveniste J
    Eur J Pharmacol; 1986 Apr; 123(2):197-205. PubMed ID: 3086108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of verapamil and diltiazem on human platelet function.
    Addonizio VP; Fisher CA; Strauss JF; Wachtfogel YT; Colman RW; Josephson ME
    Am J Physiol; 1986 Mar; 250(3 Pt 2):H366-71. PubMed ID: 3006516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet.
    Janero DR; Burghardt B; Burghardt C
    Thromb Res; 1988 Jun; 50(6):789-802. PubMed ID: 3413730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.